Nuvation Bio Inc. Class A Common Stock vs Quantum Computing Inc — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while Quantum Computing Inc trades at $7.57 (market cap $1.72B). The key difference: Nuvation Bio Inc. Class A Common Stock and Quantum Computing Inc are close in size by market cap, and Nuvation Bio Inc. Class A Common Stock is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and Quantum Computing Inc for 25 Days on average.
| NUVB | QUBT | |
|---|---|---|
Market Cap | $1.71B | $1.72B |
Volume | 5,448,712 | 7,242,201 |
Sector | Health | Technology |
52-Week High | $9.54 | $21.78 |
52-Week Low | $3.41 | $6.31 |
Typical Hold Time | 0 Days | 25 Days |
Enterprise Value | $1.30B | $791.72M |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Quantum Computing Inc. (QUBT) trades at $7.62, down 3.05% today, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and negative cash flow pose challenges.
Analysts maintain a bullish stance with a $17.33 consensus target (75% buy ratings), seeing potential in QCi's quantum technology expansion. However, execution risks, continued losses, and high valuation multiples (P/S 160.95) require careful consideration. The stock offers high-risk, high-reward potential for investors comfortable with speculative quantum computing plays.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →